• Mission Statement

    Our mission is to develop innovative technology with steering capability that will enable greater precision while targeting difficult to reach lung nodules.

    Clinical Differentiation

    Endobronchial tools that offer articulation at the distal tip to enable physicians to reach difficult targets with predictable tool positioning and enhanced precision, including those outside the airway.

  • Facts about Lung Cancer

    #1

    Lung cancer (both small cell and non-small cell) is the second most common cancer ... and by far the leading cause of cancer death , making up almost 25% of all cancer deaths. 1

    20%

    National Lung Screening Trial found that annual screening with Low-Dose Computed Tomography (LDCT) was associated with a 20% reduction in mortality in high risk patients.2

    1.6M

    Pulmonary nodules are identified in approximately 1.6 million patients per year in the US3

  • Lung Cancer Screening Criteria4,5

     

    U.S. Preventive Services Task Force advises that health care providers, and people at increased risk for lung cancer, follow the recently updated recommendations for annual lung cancer screening

     

    These organizations recommend yearly lung cancer screening with LDCT scans for people who:

    • Are 50 to 80 years old and in fairly good health, and...
    • Currently smoke or have quit in the past 15 years, and...
    • Have at least a 20 pack-year smoking history.

    In addition, it’s important that people who are going to be screened:

    • Receive counseling to quit smoking if they currently smoke,
    • Have been told by their doctor about the possible benefits, limits, and harms of screening with LDCT scans,
    • Can go to a center that has experience in lung cancer screening and treatment.

  • Executive Team

    Sasha Schrode

    President & CEO

    Duke Rohlen

    Executive Chairman

    Joe Koblish

    CTO

    Aftab Kherani, MD

    Executive Vice Chairman

    Doug Koo

    CFO

    Jocelyn Jackson

    VP of Finance

    Cason Kynes

    VP of Business Development

    Sarah St. Laurent

    Human Resources Manager

    Eliza Lawrence

    VP of Clinical

  • Development Team

    Ken Berliner

    R&D Manager, Principal Engineer

    Eza Koch

    Principal Engineer

    Chau Cao

    Senior Technician

    Riley Ennis

    R&D Engineer

    Maritza Fuerte

    R&D Engineer

  • Clinical Advisory Team

    Jeremy Durack, MD

    Chief Clinical Officer, Ajax Health and Cordis Accelerator

    Andrew Haas, MD, PhD

    Director, Interventional
    Pulmonology and
    Thoracic Oncology,
    Hospital of the University
    of Pennsylvania

    Michael Machuzak, MD

    Interventional Pulmonologist & Associate in Pulmonary, Allergy & Critical Care. The Cleveland Clinic Cancer Center.

    Momen Wahidi, MD

    Interventional Pulmonologist, Professor of Medicine, Duke University Hospital, Duke Cancer Center

    Mohit Chawla, MD

    Interventional Pulmonologist & Chief of Pulmonary, Memorial Slone Kettering

    Eric Seeley, MD

    Director, Bronchoscopy and Interventional Pulmonary Medicine,

    UC San Francisco

    George Cheng, MD, PhD

    Medical Director, Interventional Pulmonary, Bronchoscopy & Pleural Services and Associate Professor of Medicine,

    UC San Diego

    Kyle Hogarth, MD

    Director of Bronchoscopy, Professor of Medicine, Medical Director, University of Chicago. Founder of the Society for Advanced Bronchoscopy

    Alexander Chen, MD

    Interventional Pulmonogist, Instructor of Medicine, Washington University in St. Louis, Siteman Cancer Center

  • CONTACT US

    Please reach out to learn more.

    3350 Scott Blvd. STE 37B Santa Clara, CA, 95054, USA
    info@serpexmedical.com
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More